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Over the past 20 years, research into the causes of autism 
has expanded due to technological advances in basic and 
medical science. The portrayal of autistic individuals by the 
entertainment media in films such as ‘Rain Man’ and, most 
recently ‘Snowcake’, as well as the publicity surrounding the 
suggested role of vaccines in the causation of the disorder, 
has heightened public awareness of this condition. Because 
parents are most likely to approach a paediatrician when 
concerned about their child’s development, it is imperative 
that paediatricians be able to recognise warning signs of autism 
and explain the pathology and causation of this condition, and 
be familiar with local management and intervention options 
available.
Epidemiology
Autism is a complex developmental brain disorder defined by 
a core triad of symptoms, namely impaired communication 
and social interaction as well as restricted and repetitive 
interests and activities.1 The prevalence of autism in the USA 
and Europe has increased dramatically from 2 - 5 to 15 - 60 
per 10 000 children; whether this is due to the use of broader 
diagnostic criteria, greater awareness, and/or a real rise in the 
number of cases due to altered environmental factors is not 
currently clear.2,3 In South Africa no statistics on autism are 
available, but there is no reason to think that the prevalence 
of the condition, which knows no socio-economic or ethnic 
boundary, will be any lower. Typically boys are more frequently 
affected than girls, with a male/female ratio varying from 2:1 
to 15:1 depending, among other factors, on the particular form 
of autism.4
Clinical signs and symptoms
The Diagnostic and Statistical Manual of Mental Disorders, 
4th edition (DSM-IV), characterises different pervasive 
developmental disorder categories: Autistic Disorder (AD), 
Asperger’s Syndrome (AS) and Pervasive Developmental 
Disorder, Not Otherwise Specified (PDD-NOS). However, 
the presence and intensity of DSM-IV symptoms are highly 
variable between individuals, perhaps pointing to further 
aetiologically defined subtypes; the term autistic spectrum 
disorders (ASD) is therefore currently favoured to describe 
these conditions collectively.5 Furthermore, ASD often coexists 
with other genetic, psychological and biological conditions 
that need to be considered in the differential diagnosis and 
management of a child presenting with ASD symptoms 
(reviewed in Naber et al.6). 
Parents of ASD children might recognise their child as being 
somehow ‘different’ during the first few months, or, more 
typically, seek advice during or soon after the child’s second 
year of life because of a perceptible language delay and 
lack of compensatory non-verbal communication efforts. 
Alternatively, some apparently normally developing children 
may suddenly regress and lose developmental and language 
skills, usually between the ages of 2 and 4 years. 
Although presentation of ASD is extremely varied, social 
deficits, including the lack of joint attention (defined as 
manifest enjoyment of sharing an object or event with another 
person by looking back and forth between the two) appears to 
be a reliable and early warning sign of ASD in infants.6 These 
‘good babies’ are often content to be alone, and do not appear 
to seek eye contact or attention via gestures or vocalisation. 
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Over the past two decades, both the prevalence and our understanding of autism have increased exponentially. Autism 
encompasses a group of behaviourally defined developmental disorders, collectively known as autism spectrum disorder 
(ASD), which appear to be caused by the impact of environment during early life on genetically induced susceptibility. As 
paediatricians are consulted first by most parents of children with developmental delay, they should be able to discuss the 
pathology, aetiology and management of the disorder. Although much remains to be understood, research over the last 20 years 
has shown that this disorder is treatable, and that early medical/biomedical and behavioural intervention greatly improves the 
quality of life and outcomes of children with ASD.
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At a later age, some AD and PDD-NOS children may have 
some speech, which often involves repeating script from 
favourite TV programmes or repetition of another person’s 
speech (echolalia). Some children also develop ‘giant-words’, 
where phrases are condensed into single utterances, e.g. 
‘whereareyou?’, while being unable to combine words into 
new phrases that convey true meaning.4 AS children, on the 
other hand, are often quite verbose about restricted topics of 
consuming interest to them, but are unable to express feelings 
or recognise the viewpoints or interests of others.
Older ASD children may also demonstrate atypical behaviours 
such as stereotypies including repetitive hand or finger 
movements, strange eye gazing, sniffing, licking, persistent 
toe-walking, rocking and twirling. These ‘self-stimulatory 
behaviours’ may have sensory underpinnings and, although 
often harmless, are problematic because they may hamper 
learning and appropriate play. Severely affected ASD children, 
particularly those with severe intellectual disabilities, may 
also demonstrate self-injurious behaviours, which are often 
triggered by change, frustration or fatigue.7 
Although it was once considered that up to 70% of ASD 
children are cognitively impaired, recent studies assessing fluid 
intelligence, rather than the Wechsler scales of intelligence, 
suggest that intelligence has been underestimated in ASD 
individuals.8
Although ASD predominantly involves dysfunction in 
the central nervous system (CNS), individuals with ASD 
demonstrate multiorgan system involvement, even in the 
absence of co-morbid syndromes.9 As such, many children 
with ASD present with inattention and hyperactivity, 
atypical motor development, disturbed sleep patterns, 
immune dysregulation and inflammatory conditions.10-13 
The vast majority show sensory processing difficulties, often 
involving all sensory modalities, and ranging from hypo- to 
hypersensitivity even within the same modality (for example 
auditory hypersensitivity to environmental noise, but under-
responsiveness to a human voice).14 Additionally, more than 
two-thirds of ASD children manifest gastrointestinal (GI) 
symptoms, including abdominal pain and distension, gastro-
oesophageal reflux, inflammation of the GI tract, chronic 
constipation or diarrhoea, and dysbiosis.15,16 Between 35% 
and 46% of ASD individuals also develop epilepsy, with onset 
usually around puberty.17
Prognosis is dependent on many factors, including the severity 
of symptoms and presence of comorbid conditions, capacity 
for joint attention, cognitive abilities and functional play 
skills; better outcomes are associated with early intervention 
programmes and inclusion into regular educational settings 
with typically developing peers. Although, with intervention, 
many ASD children may function fairly well in mainstream 
schools, some will manifest attention-deficit hyperactivity 
disorder (ADHD) or other learning challenges, while outcomes 
in adulthood appear to correlate best with cognitive-adaptive 
abilities.4
Pathology
Children with ASD demonstrate increased head growth, even 
when indexed to body length, during the first year or two of 
life compared with neurotypically developing children.18,19 
This initial increase in brain growth has been associated with 
an overgrowth of white matter, or myelinated fibres, which 
is thought to result in aberrant neural network development, 
with elaborate short-distance cortical connections within 
brain regions and hemispheres but reduced large-scale, long-
distance connections between regions.9 Additionally, further 
pathological changes have been noticed in the corpus callosum, 
amygdala and cerebellum of ASD brains.20,21
Aetiology: genetic, immune and  
environmental factors
ASD is highly heritable, with monozygotic twins showing 
between 60% and 92% concordance and a sibling recurrence 
rate of 3 - 8%, indicating a strong genetic component in the 
causation.22 Correlations exist between regions of chromosomes 
2, 7, 1 and 17 and ASD, and genes implicated to date include 
some involved in neurodevelopment, neuronal growth, 
synaptic and dendritic changes and neurotransmission.23 
Some of the proteins implicated by these genetic studies have 
pleiotropic functions, and may account for the multisystem 
involvement seen in ASD. Candidate gene studies also imply 
that differences in neurochemical levels (e.g. melatonin, 
serotonin, dopamine, glutamate, GABA and endorphins)24,25 as 
well as metabolism (impaired sulfoxidation and carbohydrate 
metabolism)26,27 between ASD and neurotypical individuals 
may have genetic underpinnings. 
None of the described genetic alterations are ubiquitous across 
all ASD cases, and it is accepted that, in ASD per se, genetic 
changes by themselves are unlikely to be sufficient to cause the 
disorder. Rather, ASD is probably precipitated by the action 
of the environment during early life, including fetal life, on a 
substrate rendered susceptible by genetic factors.1 
During the first and second trimesters of pregnancy, 
environmental factors such as teratogens, maternal illness, 
particularly viral infections, and maternal and paternal age, 
as well as fetal testosterone levels, are thought to increase ASD 
risk to the child.4 
The immune system is also implicated by the presence of 
autoantibodies against brain proteins in almost 40% of ASD 
subjects, as well as by studies showing increased complement 
proteins in the peripheral blood and gastrointestinal tract of 
ASD individuals.28 Moreover, the cytokine profiles in ASD 
individuals are often skewed towards T-helper cell type 2, 
while lymphocyte numbers and T-cell mitogen response may 
be decreased. 
Despite earlier claims that thimerosal, a mercury compound, in 
childhood vaccines contribute to the causation of ASD, removal 
of most thimerosal from vaccines has not led to reduction in 
ASD incidence in California.29 However, as mercury is a known 
neurotoxin, the role of environmental mercury exposure is still 
unclear.30 Similarly, reports concerning the association between 
MMR vaccination and onset of ASD are conflicting.31
Moreover, approximately 40% of ASD children demonstrate 
intestinal permeability, so that digestion products of natural 
foods are able to induce antigenic responses.32 It has been 
proposed that the partial breakdown products of gluten and 
casein, which have been shown to cross the blood-brain barrier 
and elicit opioid effects in rats, and which are present in the 
urine of some ASD children, may be responsible for autistic 
behaviours in some children.33 Removal of gluten and casein 
from the diet has been reported to reduce ASD symptoms; 
however, further controlled studies with larger sample sizes 
are required in order to reach unambiguous conclusions about 
this approach.34 
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Management
Early diagnosis
Early identification of ASD is crucial as it allows early 
intervention at physical, behavioural and medical/biomedical 
level, which has been demonstrated to improve aberrant 
behaviour and cognitive impairment.2,35 Although checklists 
and diagnostic criteria are available for identification of 
autism, their interpretation in terms of measurable behaviours 
is often difficult for those not experienced in recognising this 
disorder, particularly in very young children. In addition, 
checklists of symptom patterns are often broad enough to 
be indicative of many differential diagnoses, rather than 
specifically indicating early signs of ASD, and children with 
higher intellectual functioning are often missed. In Table I we 
therefore summarise key warning signs of ASD, drawn from 
the DSM-IV, Childhood Autism Rating Scale (CARS) and 
Checklist for Autism in Toddlers (CHAT), and attempt to give 
paediatricians concrete ways of eliciting these in very young 
children, so that they can be alerted to the need for further 
investigation by professionals such as developmental and 
educational psychologists as well as occupational therapists to 
confirm a diagnosis of ASD. These signs refer predominantly 
to social indicators, as these are often the symptoms that 
differentiate ASD from other disorders, and should be used 
together with a background of DSM-IV diagnostic criteria. 
Because siblings are at significantly increased risk, young non-
autistic siblings should also be monitored closely for early 
warning signs.36 
Medical/biomedical
An integrative medical approach is needed to manage ASD, 
and treatment should be individualised in view of the variable 
presentation. Pyschopharmacology is effective in reducing 
symptoms of behavioural problems but further studies are 
required, as evidence is limited, with some exceptions, to 
uncontrolled studies that do not include all age groups.37 
Currently, the only medically registered treatment for certain 
ASD symptoms is risperidone, a well-known antipsychotic 
used in the symptomatic management of irritability, 
agitation, aggressive and self-injurious behaviour and temper 
tantrums.38 Co-morbid obsessive-compulsive disorder, 
general anxiety disorder, or major depressive disorder are 
treated with selective serotonin-reuptake inhibitors, while 
methylphenidate, clonidine and atamoxetine are used as 
supporting medication where attention deficit symptoms, 
hyperactivity and impulsivity are present.39 Anticonvulsant 
therapy may be indicated where epilepsy and seizures occur, 
while melatonin may be of benefit in the treatment of sleep 
disorder.40
Furthermore, it should be remembered that these children 
are metabolically fragile and often benefit from biomedical 
intervention, including dietary intervention, nutritional 
support and supplementation.41,42 A change in behaviour, 
such as temper outbursts or self-injury, may be caused by 
occult gastrointestinal discomfort.7 Concomitant metabolic or 
immune disorders need to be diagnosed effectively. Parents 
may also require guidance about the use of alternative 
interventions, such as herbal remedies and homeopathic 
treatment.42,43
10        SAJCH  MARCH 2008  VOL. 2  NO. 1 
REVIEW
TAblE I. ChECklIST fOR EARly wARnIng SIgnS Of AuTISTIC SPECTRuM dISORdER In yOung 
ChIldREn
Question Test
does the child respond con-
sistently to his name being 
called?
Call just the name, without giving an instruction, while the child is engaged in an activity. 
Do this twice during the consultation to determine consistency.
Response refers to the child looking towards the person calling. Note: calling must be 
by a stranger, and not a parent, to ensure that response is to his/her name and not to 
recognition of a familiar voice.
does the child show shared 
attention and read gestures?
Point to something across the room, and observe whether the child follows the gesture, 
e.g. point to a toy while saying ’Look at that [toy] on the bookshelf.’  
Ask the child to point to something other than an object they may find desirable, e.g. 
‘Show me your nose’, or  ‘Where’s the light?’
The child should be able to do both.
does the child show expecta-
tion/anticipation during brief 
pauses in play?
Play a peek-a-boo type game with the child (for example, hide your face and reappear 
unexpectedly and then repeat this action).
The child should show facial signs of anticipation.
does the child reference the 
parent’s face for reassur-
ance?
Pick the child up unexpectedly during the consultation and observe the child’s reaction.
The child should look at the parent for help/reassurance.
does the child exhibit basic 
imitation skills?
Say:  ‘Do this’ and then perform a basic action such as clapping your hands or putting 
your hands on your head.  
The child should copy your actions immediately.
Can the child answer social 
questions?
Ask the child social questions such as ‘What is your name?’ or ‘How old are you?’
The response should not be reliant on verbal ability, but can include a show of fingers or 
a partial verbal response.
If the child is unable to give a positive response to at least five of these questions, further investigation by a professional trained to diagnose ASD, 
such as a psychologist or psychiatrist, is necessary. Averted gaze, absence of a social smile, resistance to social engagement, sensory problems (which 
may be indicated by fussy eating, sensitivity to noise, arching of the body and difficulties in potty training), and language delays are further  
indications of increased risk of ASD. Parents may be directed to Autism South Africa (http://www.autismsouthafrica.org) or the authors for infor-
mation about further intervention resources.  
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behavioural
Numerous studies have shown the benefits of initiating 
intervention programmes in children with ASD as early as 
possible, including increased IQ and social skills, and reduced 
aberrant behaviour.35,44 Behaviour intervention programmes 
can be home- or centre-based, but are most effective when skills 
learnt at centre-based programmes are reinforced daily in the 
home environment.45 Effective interventions include applied 
behaviour analysis (ABA, used to increase and maintain 
desirable adaptive behaviours, reduce repetitive behaviours 
and generalise new skills to novel environments), discrete 
trial teaching (applied within an ABA framework to improve 
attention, compliance and discrimination learning), TEACCH 
(involving the used of a highly organised physical environment, 
and predictable sequences of structured activities to improve 
skills) and relationship development intervention (activities 
that elicit interactive behaviours so that the child may discover 
the value of and become motivated to sustain positive social 
interactions).7 Additionally, therapies aimed at remediating 
processing capacities, such as occupational therapy, including 
sensory integration, and speech and language therapy are 
requisite to the rehabilitation of ASD children.7,46 Some South 
African early intervention programmes are listed on the 
Autism South Africa website (http://www.autismsouthafrica.
org).
families
Management should also be extended to care of the family of 
an ASD child, as anxiety and depression are higher in parents 
of children with ASD than those with other developmental 
syndromes.47 Support should include emotional support, 
guidance and help in locating useful intervention resources 
and referral for counselling or other appropriate services. 
Most importantly, parents need to be educated about ASD and 
the efficacy of early interventions in treating and rehabilitating 
their children.
Conclusions
While ASD has in the past been called the most devastating of 
childhood developmental disorders, progress in ASD research 
has brought a clear message in recent years: while autism 
remains challenging to manage and requires a multidisciplinary 
approach, it is treatable, and early medical/biomedical and 
behavioural intervention significantly improves the quality of 
life of both these children and their families.
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